Press release BoxID: 451181 (Ypsomed AG)
  • Ypsomed AG
  • Brunnmattstrasse 6
  • 3401 Burgdorf
  • Contact person
  • Benjamin Overney
  • +41 (34) 4244159

Shares of Ypsomed Holding AG now in the Domestic Standard of the SIX Swiss Exchange

(PresseBox) (Burgdorf, ) The application by Ypsomed Holding AG to move from the Main to the Domestic Standard segment of the stock exchange has been approved by SIX Swiss Exchange Regula-tion. The application was submitted in connection with company's previous announcement that it intended to switch the financial reporting standards it uses from IFRS (International Financial Reporting Standards) to Swiss GAAP ARR (Swiss Accounting and Reporting Recommendations) at the end of August 2011.

The switch in accounting standards necessitates a change of segment, which has been approved by SIX Swiss Ex-change Regulation. The registered shares of Ypsomed Holding AG (securities symbol: YPSN, ISIN: CH0019396990) will be traded in the Domestic Standard of the SIX Swiss Exchange for the first time on 29 September 2011. The registered shares will remain tradable at all times.

As part of the change in reporting standards, goodwill in the amount of CHF 312 million is to be offset against equity. As of 31 March 2011, the equity of Ypsomed Holding AG under IFRS stands at CHF 538 million (which corresponds to an equity ratio of around 80 per cent). Taking into account all effects arising from the change, equity under Swiss GAAP ARR amounts to some CHF 225 million (as at 31 March 2011), corresponding to a new equity ratio of 64 per cent. Ypsomed Holding AG continues to have a sound financial footing. The change in reporting standards will not have a material impact on the income statement. A detailed description of the impact of the change will be announced in the semi-annual report (3 November 2011).

Ypsomed AG

The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication and a well-known diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the Disetronic Group, offers insulin pumps, injection systems and pen needles for diabetes, growth hor-mone and infertility treatments as well as for other therapeutic purposes. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufac-turing sites in Switzerland as well as leading independent diabetes product sales companies throughout Europe. The Ypsomed Group employs approximately 1'150 employees.